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Abstract
Background: Currently is not feasible using conventional spirometry as a screening method in Primary Care
especially among smoking population to detect chronic obstructive pulmonary disease in early stages. Therefore,
the FUMEPOC study protocol intends to analyze the validity and reliability of Vitalograph COPD-6 spirometer as
simpler tool to aid screening and diagnosis of this disease in early stages in primary care surgery.
Methods / Design: Study design: An observational, descriptive study of diagnostic tests, undertaken in Primary
Care and Pneumology Outpatient Care Centre at San Juan Hospital and Elda Hospital. All smokers attending the
primary care surgery and consent to participate in the study will undergo a test with Vitalograph COPD-6
spirometer. Subsequently, a conventional spirometry will be performed in the hospital and the results will be
compared with those of the Vitalograph COPD-6 test.
Discussion: It is difficult to use the spirometry as screening for early diagnose test in real conditions of primary
care clinical practice. The use of a simpler tool, Vitalograph COPD-6 spirometer, can help in the early diagnose and
therefore, it could improve the clinical management of the disease.
Background
Chronic obstructive pulmonary disease (COPD) is
defined as a preventable and treatable disease with some
significant extrapulmonary effects that may contribute
to the severity of symptoms in individual patients. Its
pulmonary component is characterized by airflow limita-
tion that is not fully reversible. The airflow limitation is
usually progressive and associated with an abnormal
inflammatory response of the lung to noxious particles
and gases [1].
The association between tobacco and COPD is well
known and the best option to prevent a high risk of suf-
fering from COPD for these patients is to quit this
smoking habit [2].
By means of epidemiological studies it has been quan-
tified that COPD is a common problem and that the
fact of being under-diagnosed and undertreated makes
its prognosis worse [3-7]. COPD is usually classified in 4
stages according to its severity. The latest evidences in
COPD have proven that early detection in stages 1 and
specially in stage 2 achieve significant improvements in
the natural history of the disease [8,9].
Spirometry is currently the standard assessment tool
for diagnosing, staging and monitoring disease progres-
sion. It is considered the most objective and reproduci-
ble measurement of airflow limitation [1].
The ratio of the two measurements (FEV1 ⁄ FVC) is cal-
culated to assess a patient’s lung function. In patients with
COPD, FEV1 and FVC readings, as well as FEV1 ⁄ FVC
ratios, will be lower than predicted (reference) values
based on age, sex, height and race. Airflow limitation is
clinically confirmed when the FEV1 ⁄ FVC postbronchodi-
lator value is < 0.70 [1].
Various types of spirometers may be used in assessing
and monitoring COPD. But conventional spirometry is
difficult to use in primary care because lack of time and
need of specific training. Recently other types of spirom-
eters have been introduced that are portable, readily
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lower needs of instruction and training in spirometry tech-
niques, healthcare providers can easily incorporate spiro-
metry into their practices and increase the likelihood of
earlier detection of COPD among their patients [10]
Therefore, it was decided to develop this study in
order to establish the validity and reliability of Vitalo-
graph COPD-6 spirometer (COPD-6), and to determine
the prevalence of undiagnosed COPD in smokers.
The COPD-6 identifies likely cases of COPD by mea-
suring patients’ obstructive index and FEV1/FEV6 ratio.
Those whose measurements are within normal range
can be screened out, allowing diagnostic spirometry
resources to be focussed on those most at risk. A pre-
vious study about COPD shows acceptable validity
indexes but another one shows low sensitivity [11,12].
Methods / Design
Main objective
To establish the validity and reliability of COPD-6 com-
pared with conventional spirometry (CS).
Specific objectives
1. To determine the prevalence of undiagnosed COPD
in smokers.
2. To establish the saving times in the primary care
setting by using COPD-6 before CS instead of CS only.
Design
FUMEPOC is an observational descriptive study of diag-
nostic tests.
Setting
T h es a m p l ew i l lb er e c r u i t e df r o mt h ep r o v i n c eo fA l i -
cante (Spain) and, specifically, the population receiving
healthcare from 5 primary care surgeries at Elda Health
Department and San Juan Health Department. So 5
Health centres and 2 Hospitals were involved.
Study Population
Patients 45 years of age and over who are smokers with
a pack-year index greater than 10, without known
respiratory disease attending a primary care consultation
will be included (Table 1). Patients who refuse to per-
form spirometry or not giving in the informed consent
were excluded.
Patients undergo a test with Vitalograph COPD-6 spi-
rometer. Subsequently, a spirometry (Datospir-120) will
be performed as the gold standard test at the reference
hospital and the results will be compared. Patients with
acute respiratory disease will make the both tests in a
different day once the acute disease has disappeared (at
least 6 weeks after acute disease).
For sample size calculating, after bibliography search-
ing, high variability in sensitivity and specificity criteria
was found. For that reason we assume the maximum
uncertainty. Thus, the sample size is calculated by
accepting a sensitivity or specificity = 50%. A 95% confi-
dence level and a 5% precision are assumed. Because of
the characteristics of the transversal design of the study,
in which patients are screened by the regular family
physician, and the absence of complex tests or high-risk
tests, we suppose a low percent loss. Therefore we
assume a 20% loss. According these assumptions,
approximately 480 patients will be needed. Calculations
are made with qualitative variables formula for infinite
populations in the estimation of a validation parameter
(sensitivity / specificity), subsequently the correction for-
mula is applied.
Methods of Data Collection
The number of primary care physicians (PCP) who will
participate in the study should be about 40. Each PCP
will be trained on the screening tool (COPD-6) and
after that will select 10 consecutive patients from
daily clinical practice who meet the inclusion criteria
(Table 1). Once the patient is included, PCP applied
the screening test and asks the patient about some
related variables (Table 2). All included patients
(screening positive or negative) will be referred to per-
form the gold standard test, CS, to be done at the
reference Hospital of San Juan or Elda. Figure 1 pro-
vides a flow diagram of the study.
COPD will be diagnosed according to the most widely
accepted criteria, that is, FEV1/FVC < 0.7 and a history
of smoking habit. The severity of COPD will be deter-
mined according to the GOLD criteria: I (FEV1 > 80%,
II (FEV1: 50-80%), III (FEV1: 30-49%); IV (FEV1 < 30%)
Vitalograph COPD-6 spirometer. Interpretation of the
results
The following results were considered: NORMAL
(FEV1/FEV6 > 0,7), STAGE I: Mild (FEV1/FEV6 < 0,7 y
FEV1 > 80%), STAGE II (FEV1/FEV6 < 0,7 y FEV1 <
80%), STAGE III (FEV1/FEV6 < 0,7 y FEV1 < 50%) and
STAGE IV: Severe (FEV1/FEV6 < 0,7 y FEV1 < 30%).
Measurements
Table 2 shows all the study variables and the collection
method. Smoking status will be measured according to
Table 1 Criteria to include patients in the FUMEPOC
study
Age 45 years or older
Smokers with pack-year index greater than 10
Free of known respiratory disease
Informed consent
Gil-Guillén et al. BMC Public Health 2011, 11:413
http://www.biomedcentral.com/1471-2458/11/413
Page 2 of 6WHO’s Smoking and tobacco Use Policy. A smoker is
defined as someone who smokes any tobacco product,
either daily or occasionally.
Statistical Analysis
Univariate and bivariate analysis will be performed to
describe the variables and to analyze validity indicators.
For those related to the spyrometers’ screening, the sen-
sitivity, specificity, positive predictive value and negative
predictive value (PPV and NPV) and likelihood ratio will
be calculated; for the values of the diagnostic tests
which follow a quantitative scale the ROC curve (recei-
ver operating characteristic) will be used in order to
facilitate the cut-off point.
Confidence interval is used at 95% for all variables.
Ethical and Legal Issues
The FUMEPOC study protocol has been reviewed and
approved by the Committee for Ethics and Clinical
Trials of San Juan Hospital (Comite Ético de Investiga-
ción Clínica (CEIC) de Hospital de San Juan)
Legal Aspects
The study is conducted according to the standards of
the International Guidelines for Ethical Review of Epide-
miological Studies (Council for International Organiza-
tions of Medical Sciences- CIOMS-Geneva, 1991) and
the recommendations of the Spanish Society of Epide-
miology about the review of ethical aspects of epidemio-
logical research.
Confidentiality of the data All information relative to
the patient’s identity is considered confidential. The data
generated during the study will be handled according to
the Spanish Law 5/1999 and corresponding norms. All
of the researchers will be required to sign a confidential-
ity agreement in order to access the study data.
Informed consent All patients must read the “Patient
Information Form” and sign a document giving in
consent.
Discussion
COPD is a leading cause of morbidity and mortality
worldwide, and results in an economic and social bur-
den that is both substantial and increasing. The preva-
lence and morbidity data greatly underestimate the total
burden of COPD because the disease is usually not diag-
nosed until it is clinically apparent and moderately
advanced [2].
Currently, COPD is a more costly disease than asthma
and, depending on country 50-75% of the costs are for
health services associated with exacerbations. Tobacco
s m o k ei sb yf a rt h em o s ti m p o r t a n tr i s kf a c t o rf o r
COPD worldwide. Other important risk factors are
occupational exposures, socio-economic status and
genetic predisposition [2].
COPD is the fourth-leading cause of death in the USA
and Europe, and COPD mortality in females has more
than doubled over the last 20 yrs [13].
This study is developed in the Health Departments of
San Juan and Elda (Alicante, Spain), with enough
research personnel and material resources for its imple-
mentation (spirometers-CS-, COPD-6 spirometers, clini-
cal rooms, and others). Family doctors of these
Departments will perform the study once a training
course was made.
An early diagnosis of COPD is important, since
depending on the stage in which it is made, different
treatments or actions can be applied. This is important
because currently there are no treatments that can
reverse the natural history of disease in later stages [6,7].
Some limits of this diagnostic tests study are related to
those from diagnostic observational studies for the vali-
dation of a measure device, such as diagnosed verifica-
tion bias. It must be taken into account to consider the
validity of the results.
In order to solve some kind of bias some measures
will be taken. Both tests should be applied to all patients
(positive and negative screening results) in order to
obtain the diagnoses confirmation or not in all cases.
Patients were selected from Primary care setting by
their family doctors so the percentage of non-responders
is expected to be low avoiding selection bias.
T h i ss t u d yi n c l u d e so n l ys m o k e r sb e c a u s eo ft h e
increased risk for COPD but in the future and depend-
ing on the results a second phase will be conducted
with ex-smokers.
The “gold standard test” should be applied blindly to
the evaluator that is not aware of the outcome of the
screening test in order to avoid information bias. So
that, the COPD6 result will be not included in the
Table 2 Study variables in FUMEPOC study
Variables Collection method
Socio-demographic Clinical record
Smoking status Clinical record
Pack-year index = (no cigarettes per
day/20) × smoking years
Clinical record
Symptoms (morning cough, sputum)
and others (specify)
Clinical record
Spirometer device COPD-6 (FEV 1, FEV
6 and FEV1/FEV6)
Device result
Evaluation of screening test results Test
Personal history and cardiovascular
diseases
Clinical record
Consultation Time (physician) Timer/Chronometer (minutes)
Referral Time (patient) Days
Cholesterol (HDL and LDL), PAS, PAD,
BMI
Laboratory results taken from
the clinical record
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Page 3 of 6petition sheet of spirometry in the hospital and the
result of screening will be not given to the patient until
both tests have been performed. So a final report on the
results of the two tests will be sent to patients.
Prior to the start of the study reproducibility of the
test must be assessed. A poorly reproducible test may
affect the validity of the results. In our study the screen-
ing instrument COPD-6, is a perfectly reproducible test
in patients with different clinical and pathological states.
Regarding “gold standard” selection, Conventional
Spirometry is the gold standard for diagnosing the dis-
ease and monitoring its progression as it is non-invasive,
standardised, reproducible, and objective. Functional
diagnosis of COPD is important for identifying and
quantifying airflow limitation, reversibility, disease sever-
ity and exacerbations. Functional diagnosis is also
important for long-term therapeutic monitoring and for
establishing the need for pulmonary rehabilitation [14].
Spirometry ought to be used in primary care as a
screening tool for the early detection of COPD in all
patients > 45 years of age who are currently smoking, as
well as those with respiratory symptoms [15].
But Spirometry is difficult to use widely in PC setting.
To implement screening tools in primary care it needs
to be trough a simpler, cheaper test because of the pri-
mary care clinic conditions [16].
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Figure 1 Flow diagram of the FUMEPOC study.
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sional to make an objective measurement of airflow lim-
itation and the degree to which it is reversible, and is an
important tool for accurate diagnosis and effective man-
agement of chronic respiratory diseases including
asthma and COPD [17]. However, spirometry remains
underused in primary care [18,19]. Barriers to perform-
ing spirometry in community settings include lack of
access to calibrated spirometers, inadequate training in
performing spirometry, price of conventional spirom-
eters, lack of quality-control systems to ensure accurate
results, and inadequate interpretation skills among
health professionals performing the test [20,21].
Having a simple screening tool adapted to the primary
care setting would detect COPD in early stages and the
number of patients referred to CS will be lower. It could
help to establish a protocol to facilitate high risk people
screening with high rates of compliance. This is an
effort in terms of prevention, which can result in fewer
later stages cases of the disease and consequently, better
quality of life for patients. In addition it could help sav-
ings for the healthcare burden.
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